AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31126618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided intravenous line placement
Number of subjects: 167
Study 31126618 — intervention group
Group type: COMPARATOR
Intervention: Traditional intravenous line placement
Number of subjects: 167
Study 29144720 — intervention group
Group type: EXPERIMENTAL
Intervention: gammaCore adjunct to standard of care (SoC)
Number of subjects: 0
Study 29144720 — intervention group
Group type: COMPARATOR
Intervention: SoC alone
Number of subjects: 0
Study 24420651 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based preventive intervention
Number of subjects: 1874
Study 23579522 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 ESB
Number of subjects: 90
Study 23579522 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 and T4 ESB
Number of subjects: 90
Study 23579522 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 ESB in association with T3 ramicotomy
Number of subjects: 90
Study 23579522 — intervention group
Group type: COMPARATOR
Intervention: Control group (T4 ESB)
Number of subjects: 90
Study 21461352 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week intensified exercise training (ET)
Number of subjects: 0
Study 19210281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care (PC)
Number of subjects: 107
Study 19210281 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 107
Study 16887480 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (n=3125)
Number of subjects: 6241
Study 16887480 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (n=3116)
Number of subjects: 6241
Study 15499298 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynotest Tg‐Plus immunoradiometric assay (IRMA)
Number of subjects: 157
Study 15499298 — intervention group
Group type: COMPARATOR
Intervention: HTGK‐2 IRMA
Number of subjects: 157
Study 11433707 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human nerve growth factor (rhNGF)
Number of subjects: 1019
Study 11433707 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1019
Study 9562733 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (INR: 2.0‐3.0)
Number of subjects: 4500
Study 9562733 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetylsalicylic acid (30-325 mg/day) plus dipyridamole (400 mg daily)
Number of subjects: 4500
Study 9562733 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid only (30-325 mg/day)
Number of subjects: 4500
Study 7962781 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) 7.5% for 20 minutes daily for 8 days
Number of subjects: 11
Study 7962781 — intervention group
Group type: EXPERIMENTAL
Intervention: Dodecyl trimethyl ammonium bromide (DTAB) 7.5% for 20 minutes daily for 8 days
Number of subjects: 11
Study 7962781 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium soap 7.5% for 20 minutes daily for 8 days
Number of subjects: 11
Study 2663160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (1 gm, intravenously or intramuscularly, daily for 3 to 11 days, mean 7 days)
Number of subjects: 118
Study 2663160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 gm, intravenously or intramuscularly, daily for 3 to 11 days, mean 7 days)
Number of subjects: 118
Study 2663160 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (Control)
Number of subjects: 118
Study 2663160 — intervention group
Group type: COMPARATOR
Intervention: Cefonicid (Control)
Number of subjects: 118
Study 31371167 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention for distal femoral fractures (specifics not provided)
Number of subjects: 11
Study 28865586 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC treatment by means of Y-connector
Number of subjects: 21
Study 28865586 — intervention group
Group type: COMPARATOR
Intervention: bridge-VAC treatment
Number of subjects: 21
Study 26148618 — intervention group
Group type: COMPARATOR
Intervention: Healthy people (control group)
Number of subjects: 235
Study 26148618 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer patients
Number of subjects: 235
Study 23113965 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan (20 mg/d) plus Rosuvastatin (10 mg/d)
Number of subjects: 40
Study 23113965 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine (20 mg/d) plus Rosuvastatin (10 mg/d)
Number of subjects: 40
Study 21586508 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol 160/4.5 µg, 2 × 2 treatment
Number of subjects: 8424
Study 21586508 — intervention group
Group type: COMPARATOR
Intervention: budesonide/formoterol 160/4.5 µg, 1 × 2 treatment
Number of subjects: 8424
Study 17683501 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac (100 mg)
Number of subjects: 100
Study 17683501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16433868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (3 mg min(‐1) i.v. infusion over 100 min)
Number of subjects: 8
Study 16433868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline with ciprofloxacin
Number of subjects: 8
Study 16433868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline with rifampicin
Number of subjects: 8
Study 16433868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 8
Study 16433868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline after rifampicin pretreatment
Number of subjects: 8
Study 16433868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline and its metabolites
Number of subjects: 8
Study 16433868 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.v. infusion over 100 min)
Number of subjects: 8
Study 11996479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide/carboplatin/etoposide (ICE) chemotherapy consisting of ifosfamide 1800 mg/m2/day (on day 0-4), carboplatin 400 mg/m2/day (on day 0-1), and etoposide 100 mg/m2/day (on day 0-4)
Number of subjects: 11
Study 11996479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide/carboplatin/etoposide (ICE) chemotherapy
Number of subjects: 11
Study 11996479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide/carboplatin/etoposide (ICE) chemotherapy followed by post-ICE therapy
Number of subjects: 11
Study 9952016 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephro‐Vite Rx (once daily for 3 weeks)
Number of subjects: 11
Study 7750007 — intervention group
Group type: EXPERIMENTAL
Intervention: Active extract (Alpare Parietaria) with a targeted maintenance dose of 12,500 BUs for 2 years
Number of subjects: 36
Study 7750007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7750007 — intervention group
Group type: EXPERIMENTAL
Intervention: Active extract (Alpare Parietaria)
Number of subjects: 36
Study 2245814 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralphate
Number of subjects: 51
Study 2245814 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study 6251487 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride-calcium pyrophosphate (SnF2-CPP) dentifrice
Number of subjects: 1337
Study 6251487 — intervention group
Group type: COMPARATOR
Intervention: Placebo control dentifrice
Number of subjects: 1337
Study 6141896 — intervention group
Group type: EXPERIMENTAL
Intervention: loprazolam 1 mg
Number of subjects: 40
Study 6141896 — intervention group
Group type: EXPERIMENTAL
Intervention: loprazolam 2 mg
Number of subjects: 40
Study 6141896 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 30664462 — intervention group
Group type: EXPERIMENTAL
Intervention: PoP website (The Power of Placebos)
Number of subjects: 350
Study 30664462 — intervention group
Group type: COMPARATOR
Intervention: Control website (existing information leaflets from UK trials)
Number of subjects: 350
Study 30672230 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle tension staged acupuncture
Number of subjects: 62
Study 30672230 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 62
Study 26813298 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX) 150 mL, 2 U/mL
Number of subjects: 46
Study 26813298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (150 mL 0.9% NaCl)
Number of subjects: 46
Study 26813298 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX)
Number of subjects: 46
Study 24644183 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxyflurane (MEOF)
Number of subjects: 100
Study 24644183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22988932 — intervention group
Group type: EXPERIMENTAL
Intervention: SKP-1052 (2.5 mg)
Number of subjects: 30
Study 22988932 — intervention group
Group type: EXPERIMENTAL
Intervention: SKP-1052 (5 mg)
Number of subjects: 30
Study 22988932 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT (5 mg)
Number of subjects: 30
Study 22988932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19260039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognizin citicoline 2,000 mg/day
Number of subjects: 0
Study 19260039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognizin citicoline 500 mg/day
Number of subjects: 0
Study 19260039 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 17414932 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/r at a dose of 300/100 mg once daily (Period I)
Number of subjects: 15
Study 17414932 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV at a dose of 300 mg once daily plus LPV/r at a dose of 400/100 mg twice daily (Period II)
Number of subjects: 15
Study 17414932 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/r at a dose of 300/100 mg once daily plus LPV/r at a dose of 400/100 mg twice daily (Period III)
Number of subjects: 15
Study 17414932 — intervention group
Group type: COMPARATOR
Intervention: LPV/r at a dose of 400/100 mg twice daily (historical control)
Number of subjects: 15
Study 16095446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff Pressure Release Valve (CPRV) set to 25 cmH2O
Number of subjects: 50
Study 16095446 — intervention group
Group type: COMPARATOR
Intervention: Control group (without CPRV)
Number of subjects: 50
Study 11897259 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional energy drink (FED) - 250 ml containing sucrose, glucose, 80 mg caffeine, taurine, glucuronolactone, and vitamins
Number of subjects: 12
Study 11897259 — intervention group
Group type: COMPARATOR
Intervention: Control drink - 250 ml with the same volume and taste but without caffeine, taurine, and glucuronolactone
Number of subjects: 12
Study 10353472 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measurement in group A at onset of infection (d1)
Number of subjects: 563
Study 10353472 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Reactive Protein (CRP) measurement in group A at onset of infection (d1)
Number of subjects: 563
Study 10353472 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measurement in group B at onset of infection (d1)
Number of subjects: 563
Study 10353472 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Reactive Protein (CRP) measurement in group B at onset of infection (d1)
Number of subjects: 563
Study 10353472 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin (PCT) measurement in group C (control) at d1
Number of subjects: 563
Study 10353472 — intervention group
Group type: COMPARATOR
Intervention: C-Reactive Protein (CRP) measurement in group C (control) at d1
Number of subjects: 563
Study 10353472 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin (PCT) measurement in group C (control) at d3
Number of subjects: 563
Study 10353472 — intervention group
Group type: COMPARATOR
Intervention: C-Reactive Protein (CRP) measurement in group C (control) at d3
Number of subjects: 563
Study 10353472 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin (PCT) measurement in group C (control) at d5
Number of subjects: 563
Study 10353472 — intervention group
Group type: COMPARATOR
Intervention: C-Reactive Protein (CRP) measurement in group C (control) at d5
Number of subjects: 563
Study 8669598 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 16
Study 8669598 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 16
Study 8669598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 16
Study 2213262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic phototherapy
Number of subjects: 46
Study 2213262 — intervention group
Group type: COMPARATOR
Intervention: Traditional phototherapy
Number of subjects: 46
Study 6110383 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131 (0.3 mg or 0.6 mg subcutaneous injection)
Number of subjects: 12
Study 6110383 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (not specified in dosage)
Number of subjects: 12
Study 31034809 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning system for endoscopic diagnosis of EGC
Number of subjects: 365
Study 28580602 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded maternal voices
Number of subjects: 40
Study 28580602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no recorded maternal voices)
Number of subjects: 40
Study 27559351 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Gold Label
Number of subjects: 186
Study 27559351 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Fuji Plus
Number of subjects: 186
Study 23683764 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (n=92)
Number of subjects: 185
Study 23683764 — intervention group
Group type: COMPARATOR
Intervention: Leg-elevation position (n=93)
Number of subjects: 185
Study 21861032 — intervention group
Group type: EXPERIMENTAL
Intervention: HP (2 applications of 10 min each)
Number of subjects: 100
Study 21861032 — intervention group
Group type: EXPERIMENTAL
Intervention: HP + LED laser (2 applications of 10 min each/45 s of light activation)
Number of subjects: 100
Study 21861032 — intervention group
Group type: EXPERIMENTAL
Intervention: HP
Number of subjects: 100
Study 21861032 — intervention group
Group type: EXPERIMENTAL
Intervention: HP + LED laser
Number of subjects: 100
Study 21861032 — intervention group
Group type: COMPARATOR
Intervention: Control (unbleached)
Number of subjects: 100
Study 20530938 — intervention group
Group type: EXPERIMENTAL
Intervention: 75‐gram oral glucose tolerance test (oGTT)
Number of subjects: 25000
Study 20530938 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPO data
Number of subjects: 25000
Study 17192503 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg d-methylphenidate (d-MPH)
Number of subjects: 25
Study 17192503 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-methylphenidate (d-MPH)
Number of subjects: 25
Study 17192503 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg d-methylphenidate (d-MPH)
Number of subjects: 25
Study 17192503 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg d-methylphenidate (d-MPH)
Number of subjects: 25
Study 17192503 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg d-methylphenidate (d-MPH)
Number of subjects: 25
Study 15222108 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly taxol (TXL) therapy at 60 mg/m2 once a week for 3 weeks with or without a rest week.
Number of subjects: 36
Study 12392584 — intervention group
Group type: COMPARATOR
Intervention: 150 mg oseltamivir alone (Treatment A)
Number of subjects: 12
Study 12392584 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oseltamivir with 20 ml Maalox suspension (Treatment B)
Number of subjects: 12
Study 12392584 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oseltamivir with four Titralac tablets (Treatment C)
Number of subjects: 12
Study 11122796 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin chemotherapy and radiation therapy
Number of subjects: 0
Study 11122796 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0
Study 7546755 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl
Number of subjects: 102
Study 7546755 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-fentanyl
Number of subjects: 102
Study 7546755 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane/droperidol
Number of subjects: 102
Study 2125402 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone (7.2 kcal/day, D5W + C)
Number of subjects: 68
Study 2125402 — intervention group
Group type: COMPARATOR
Intervention: Glucose and a conventional amino acid solution (7.2 kcal/day and 0.15 gN/day, CAA + C)
Number of subjects: 68
Study 2125402 — intervention group
Group type: COMPARATOR
Intervention: Glucose and branched chain amino acid enriched solution (7.2 kcal/day and 0.14 gN/day, BCAA + C)
Number of subjects: 68
Study 2125402 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose alone (7.2 kcal/day, D5W)
Number of subjects: 68
Study 2125402 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and a conventional amino acid solution (7.2 kcal/day and 0.14 gN/day, CAA)
Number of subjects: 68
Study 6770952 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet
Number of subjects: 40
Study 6770952 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-protein diet
Number of subjects: 40
Study 30285850 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic approach to recruitment of care homes
Number of subjects: 245
Study 30285850 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted approach to recruitment of care homes
Number of subjects: 245
Study 30285850 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment approach
Number of subjects: 245
Study 26650380 — intervention group
Group type: EXPERIMENTAL
Intervention: Central fat mass
Number of subjects: 0
Study 26650380 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral fat mass
Number of subjects: 0
Study 25440099 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Blalock-Taussig shunt (MBTS)
Number of subjects: 240
Study 25440099 — intervention group
Group type: COMPARATOR
Intervention: Right ventricle to pulmonary artery shunt (RVPAS)
Number of subjects: 240
Study 25440099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both shunt types
Number of subjects: 240
Study 22686571 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscopy-guided insertion technique
Number of subjects: 108
Study 22686571 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (digital manipulation)
Number of subjects: 108
Study 20052502 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 55
Study 20052502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 55
Study 18198398 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron fortified ready-to-eat cereal (30 g providing 7.1 mg iron/day) plus pumpkin seed kernels (30 g providing 4.0 mg iron/day) for four weeks
Number of subjects: 8
Study 18198398 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron fortified ready-to-eat cereal and pumpkin seed kernels
Number of subjects: 8
Study 15177859 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 107
Study 15177859 — intervention group
Group type: COMPARATOR
Intervention: Supported sitting position
Number of subjects: 107
Study 12474072 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid-fortified wheat breakfast rolls (200 microg/roll) - Group L
Number of subjects: 29
Study 12474072 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid-fortified wheat breakfast rolls (400 microg/roll) - Group H
Number of subjects: 29
Study 9491868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 223
Study 9491868 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert
Number of subjects: 223
Study 7848951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam (20 mg, 2 mL)
Number of subjects: 80
Study 7848951 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (2 mL)
Number of subjects: 80
Study 7848951 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (tenoxicam and saline)
Number of subjects: 80
Study 3184393 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (salbutamol) inhalation
Number of subjects: 10
Study 3184393 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study 29442239 — intervention group
Group type: COMPARATOR
Intervention: MA 320 mg/day plus placebo
Number of subjects: 90
Study 29442239 — intervention group
Group type: EXPERIMENTAL
Intervention: MA 320 mg/day plus celecoxib 200 mg/day
Number of subjects: 90
Study 28295847 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention (monthly home visits by nurses and physiotherapists for 1 year)
Number of subjects: 153
Study 28295847 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 153
Study 25608502 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioning
Number of subjects: 90
Study 25608502 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion
Number of subjects: 90
Study 25608502 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 23229890 — intervention group
Group type: EXPERIMENTAL
Intervention: +mobile group
Number of subjects: 70
Study 23229890 — intervention group
Group type: COMPARATOR
Intervention: standard group
Number of subjects: 70
Study 21914503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 0
Study 21914503 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 18684777 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual lifestyle counselling (autonomy supportive and self-efficacy enhancing)
Number of subjects: 176
Study 18684777 — intervention group
Group type: COMPARATOR
Intervention: Group based rehabilitation
Number of subjects: 176
Study 16609019 — intervention group
Group type: EXPERIMENTAL
Intervention: High HOXB13/IL‐17BR expression ratio in node-negative cohort (n = 130)
Number of subjects: 256
Study 16609019 — intervention group
Group type: EXPERIMENTAL
Intervention: HOXB13/IL‐17BR ratio in node-positive cohort (n = 86)
Number of subjects: 256
Study 14596546 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0